Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Genoptix, Inc. (“Genoptix” or the “Company”) (Nasdaq: GXDX) concerning the sale of the Company to Novartis Finance Corp. for $25 in cash for every share of common stock owned in a transaction valued at approximately $470 million. The transaction is expected to close in the first half of 2011.

The investigation is focused on the potential unfairness of the deal price to Genoptix shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interests among Genoptix Board members. The stock was trading in excess of $38 per share in May 2010, and according to Yahoo! Finance at least one analyst has set a target price of $28 for Genoptix’s shares.

If you are interested in discussing your rights as a Genoptix shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010